NEUROGENIC CONTROL OF CANINE BRONCHIAL SMOOTH MUSCLE: COMPARISON OF THE NORMAL AND EXPERIMENTALLY-INDUCED HYPERRESPONSIVE STATES

Size: px

Start display at page:

Download "NEUROGENIC CONTROL OF CANINE BRONCHIAL SMOOTH MUSCLE: COMPARISON OF THE NORMAL AND EXPERIMENTALLY-INDUCED HYPERRESPONSIVE STATES"

Wesley Black
6 years ago
Views:

1 NEUROGENIC CONTROL OF CANINE BRONCHIAL SMOOTH MUSCLE: COMPARISON OF THE NORMAL AND EXPERIMENTALLY-INDUCED HYPERRESPONSIVE STATES By LUKE JEFFREY JANSSEN, B.Sc., M.Sc. A Thesis Submitted to the School of Graduate Studies in Partial Fulfilment of the Requirements for the Degree Doctor of Philosophy McMaster University

2 NEUROGENIC CONTROL OF CANINE BRONCHIAL SMOOTH MUSCLE

3 DOCTOR OF PHILOSOPHY (1990) (Biomedical Sciences) McMASTER UNIVERSITY Hamilton, Ontario TITLE: NEUROGENIC CONTROL OF CANINE BRONCHIAL SMOOTH MUSCLE: COMPARISON OF THE NORMAL AND EXPERIMENTALLY-INDUCED HYPERRESPONSIVE STATES AUTHOR: Luke Jeffrey Janssen, B.Sc. (McMaster University) M.Sc. (McMaster University) SUPERVISOR: Dr. E.E. Daniel NUMBER OF PAGES: xii, 166 ii

4 ABSTRACT Asthma is a disease characterized by airway hyperresponsiveness (AH) to various spasmogens. Ozone-inhalation causes transient AH of human and canine airway smooth muscle (ASM) and has therefore been used as a model of AR. The mechanism(s) underlying ozone-induced or asthma-related AR are not completely understood, but there is a growing body of evidence that there is a causal relationship between airway inflammation and AR. In these studies, the mechanisms regulating canine bronchial smooth muscle (3 rd to 5 th order) activit~ were investigated using intracellular microelectrodes (to monitor electrical activity) and muscle baths (to monitor mechanical activity). The effects of ozone-inhalation and inflammatory mediators on regulation of ASM tone were also investigated. Excitation of ASM (membrane depolarization and contraction) was elicited by activation of muscarinic receptors or thromboxane receptors; the former were found to be of the M3-subtype. The data indicated that pharmacomechanical (rather than electromechanical) coupling was involved. Inhibition of ASM was found to be initiated by activation of 8-adrenoceptors; these were found to be predominantly of the 8 1 subtype, though there was evidence that some 8 2 -adrenoceptors were also involved. There was evidence of physiological antagonism between cholinergic receptor-mediated excitation and adrenoceptormediated inhibition due to reciprocal effects on adenylate cyclase. iii

5 Release of acetylcholine from the cholinergic nerve endings was antagonized by activation of muscarinic receptors (H1-subtype) or adrenoceptors (both and 82- subtypes), and potentiated by activation of thromboxane receptors; these receptor populations were presumed to be located on the nerve endings. There was indirect evidence that neurotransmitter-release was also antagonized by a cyclo-oxygenase metabolite of arachidonic acid (presumably PGE 2 ). Ozone-inhalation significantly enhanced contractions in response to electric stimulation, but did not significantly a'ter those to exogenously-added cholinergic agonist or to KCl. This AH was prevented by indomethacin (cyclo~oxygenase inhibitor) or by L 670,596 (thro~oboxane receptor antagonist). It was concluded that the mechanism underlying ozone-induced AH involved decreased prejunctional inhibition (mediated by PGE 2 ) and/or increased prejunctional excitation (mediated by TxA2). iv

6 ACKNOWLEDGEMENTS lowe a great deal of thanks and credit to many people, without whom I know I could not have finished. The first of those I would like to thank are Drs. E.E. Daniel and P.M. O'Byrne who were not only very helpful, approachable, and encouraging as supervisors, but who also became role models to me. I would also like to express my thanks to: - Dr. John Smeda (particularly for helping me to develop the ability to carry out and interpret intracellular microelectrode studies) and Dr. P.K. Rangachari for their help as supervisors; - many of my colleagues who helped with the everyday tasks of finding this, making that, using (and sometimes fixing) something else, for moral support, and for their friendship. In particular, thank-you Jennifer Jury, Andrew Abela, Jocelyn otis, Cathy Lane, Graham Jones, Peter Kostka, Linda Clements, Don Maurice, Laurie Wideman, Colin Ikeson, and Bert Vicheau; - the various people involved in the administrative side of my stuc.j.es: Christel Bandomir, Denise Scott, Jean Oushenko, Mary Crechiola, and Jan Pauhl; thanks for the support you gave me when I needed it; - the Pharmaceutical Manufacturer's Association of Canada and the Medical Research Council of Canada for financial support; - my family and friends who helped break up the monotony and frustration of my studies, and encouraged me day to day; Finally, and of course most of all, thank-you Miriam for your love, support, and help (as well as the much-needed criticism and caution). v

7 TABLE OF CONTENTS Title page Description Abstract Acknowledgments Table of contents List of Tables List of Figures List of Abbreviations List of Drugs used INTRODUCTION (1) Airway smooth muscle morphology - smooth muscle - innervation - epithelium - inflammatory cells (2) Airway smooth muscle physiology -' actomyosin ATPase activity - phosphorylation of myosin - excitation-contraction coupling - pharmacomechanical coupling - electromechanical coupling - relaxation coupling mechanisms - myogenic versus neurogenic control ~ i ii iii v vi xi x xi xiii (3) Regional differences ---) rationale for this study 22 (4) Electrophysiological studies of airway smooth muscle 23 (5) Characterization of receptors - muscarinic receptors - adrenergic receptors - Schild plot analysis (6) Asthma and experimentally-induced hyperreactivity - altered activity of innervation - receptor-related pathology - altered/defective smooth muscle physiology - epithelial damage or dysfunction - inflammatory response - experimental studies of asthma (7) Objectives MATERIALS AND METHODS (ll Dissection e2l Ozone studies vi

8 (3) Organ bath studies 55 (4) Microelectrode studies 56 (5) Field stimulation 56 (6) Statistical analysis 57 (7) Drugs used 58 RESULTS 59 (1) Cholinergic control of ASM 59 - effects of muscarinic agonists on mechanical T~~ponses 59 - effects of muscarinic agonists on electrical activity 61 - characterization of receptor mediating tonic contractions 63 - effects of selective muscarinic antagonists on FS-responses 64 (2) Adrenergic control 65 - effects of 8-agonists on carbachol-induced contractions 66 selective antagonism of NE-induced relaxations 67 selective antagonism of Sal-induced relaxations 67 selective antagonism of FS-induced relaxations 69 inhibition of FS-contractions by B-agonists 70 antagonism of 8-agonist-induced inhibition of FS-contractions 71 effects of B-agonists and antagonists on electrical responses to field stimulation 73 effects of antagonists on endogenouslyreleased NE 74 (3) Influence of thromboxanes on ASM function - effects of U46619 on mechanical reactivity - pharmacological manipulation of effects of U46619 on mechanical activity - effects of U46619 on electrical reactivity - pharmacological manipulation of effects of U46619 on electrical activity (4) Ozone inhalation 79 - effects of ozone-inhalation on tissue weight 79 effects of ozone-inhalation on contractile responses 80 effects of IDM on ozone-induced hyperresponsiveness 82 effects of TxA2-antagonist on ozone-induced hyperresponsiveness 82 effects of ozone-inhalation on prejunctional versus vii

9 postjunctional mechanisms 83 DISCUSSION 84 (1) Excitation of canine bronchial smqqth muscle 84 (1.1) Postjunctional muscarinic M~-receptors 84 (1.2) Postjunctional thromboxane J~eceptors 86 (2) Modulation of excitatory neurotr('tnsmission 88 (2.1) prejunctional inhibitory M,-receptors 88 (2.2) Prejunctional excitatory mu.jcarinic receptors? 89 (2.3) Prejunctional inhibitory 8-adrenoceptors 90 (2.4) Arachidonic acid metabolites 96 (2.5) Role for adenylate cyclase? 98 (3) Inhibition of canine bronchial smooth muscle (3.1) Relaxations are predominantly 81-adrenoceptor mediated 99 (3.2) Relaxations may be partially 8 2 -receptor mediated 100 (3.3) Postjunctional versus non-junctional site of receptors 101 (3.4) NE-release not modulated by adrenoceptors 102 {4} Various aspects of ASM physiology 103 (4.1) Physiological antagonism between adrenergic and cholinergic mechanisms 103 (4.2) Continuous or background release of NE? 105 (4.3) Electromechanical vs pharmacomechanical coupling 107 (4.4) Subtypes of thromboxane receptors? 108 (5) Ozone-induced hyperresponsiveness 110 (5.1) Ozone-inhalation induces hyperresponsiveness 110 (5.2) Role of adrenergic or cholinergic mechanisms in ozone-induced hyperresponsiveness 111 (5.3) Role of arachidonic acid metabolites in ozone-induced hyperresponsiveness 112 (6) Implications of present study for asthma in humans 116 (6.1) Tracheal and bronchial smooth muscles are not comparable 116 (6.2) Canine model is inappropriate for studies relating to human species? 117 (6.3) New approaches to treating asthma-related bronchoconstriction 118 (7) Future research 120 (8) Conclusions 122 REFERENCES 124 viii

10 LIST QF TABLES 1. Effects of muscarinic agonists on electrical activity 2. Effects of a-~gonists on FS-contractions 3. Effects of selective a-antagonists on NE-induced inhibition of FS-contractiona 4. Effects of selective a-antagonists on Sal-induced inhibition of FS-contractions 5. Schild plot analysis of data in tables 5 and 6 and figures 20 and /5, ratios in control or ozone-exposed tissues 7. published pa2 values for muscarinic antagonists ix

LIST QF FIGURES 1. Apparatus used in studies 2. Effects of muscarinic agonists on mechanical activity 3. Tonic contractions induced by muscarinic agonists 4.

11 LIST QF FIGURES 1. Apparatus used in studies 2. Effects of muscarinic agonists on mechanical activity 3. Tonic contractions induced by muscarinic agonists 4. Effects of muscarinic agonists on FS-contractions 5. Effects of KCI and histamine on mechanical activity 6. Effects of muscarinic agonists on electrical activity 7. Effects of muscarinic antagonists on Oxo-contractions 8. Schild plot analysis for figure 6 9. Effects of pirenzepine on electrical activity 10. Effects of muscarinic antagonists on FS-contractions 11. Effects of NE on Cch-contractions 12. Effects of a-agonists on Cch-contractions 13. Effects of selective a-antagonists on NE-induced relaxations 14. Schild plot analysis for figure Effects of selective a-antagonists on Sal-induced relaxations 16. Effects of selective a-antagonists on FS-induced relaxations 17. Effects of ~ on FS-contractions 18.' Effects of a-agonists on FS-contractions 19. Effects of selective a-antagonists on NE-induced inhibition of FS-contractions 20. Effects of selective a-antagonists on Sal-induced inhibition of FS-contractions 21. Schild plot analysis for figures 20 and Effects of NE on FS-EJPs. 23. Effects of Iso on FS-EJPs and inhibition by propranolol 24a. Effects of Iso on FS-EJPs and inhibition by timolol 24b. Effects of Salon FS-EJPs and inhibition by timilol 25. Effects of selective a-antagonists on NE-induced inhibition of FS-EJPs 26. Effects of timolol on FS-EJPs 27. Effects of U46619 on mechanical activity 28. Effects of U46619 on mechanical activity 29. Effects of U46619 on Cch-contractions 30. Effects of blockade of thromboxane or adrenergic receptors on effects of U46619 on FS-contractions 31. Effects of blockade of thromboxane or cholinergic receptors on U46619-induced contractions 32. Effects of U46619 on electrical activity 33. Effects of U46619 on electrical activity 34. Example of procedure used in ozone-studies 35. Effects of ozone on responsiveness to FS (0.1 pps) 36. Effects of ozone on responsiveness to FS (1.0 pps) 37. Effects of ozone on responsiveness to FS (10 pps) 38. Effects of ozone on responsiveness to KCI 39. Re-normalized responses to FS ( pps) in absence of IOM or L-670, Effects of ozone on responsiveness to Cch 41. Proposed mechanisms underlying ozone-induced hyperresponsiveness x

12 LIST OF ABBREVIATIONS AA. arachidonic acid AC.. adenylate cyclase Ach. acetylcholine ADP.. adenosine diphosphate AF-DX AF-DX 116 AH airway hyperresponsiveness AP. action potential ASM. airway smooth muscle ATP adenosine triphosphate Bch. bethanechol ca++i. intracellular calcium ion camp cyclic adenosine-3',s'-monophosphate Cch. carbachol cgmp.. cyclic guanosine-3',s'-monophosphate CGRP calcitonin gene related peptide DAG diacylglycerol DMSO. dimethyls~~foxide EC x concentration eliciting x% maximal excitation EDRF.. endothelium-derived relaxing factor EJP. excitatory junction potential EpDRF.. epithelium-derived relaxing factor FS. [electrical] field stimulation GC... guanylate cyclase HETE. hydroxyeicosatetraennic acid hexa.. hexahydrosiladifenidol IC SO concentration eliciting 50% inhibition IOM indomethacin 1P3 inositol trisphosphate Iso isoproterenol Lt.. leukotriene MLCK.. myosin light chain kinase NANC.. non-cholinergic, non-adrenergic NE. norepinephrine xi

13 NMJ neuromuscular junction Oxo oxotremorine PAF. platelet activating factor PG. prostaglandin PHI. peptide histidine isoleucine PI phosphoinositol Pir... pirenzepine PK... protein kinase pps.. pulses per second Rm [cell] membrane resistance Sal. salbutamol SAV.. small agranular vesicle SEM. standard error of the means SGV.... small granular vesicle SR.... sarcoplasmic reticulum TTX.. tetrodotoxin TxA 2.. thromboxane A2 VIP..... vasoactive intestinal peptide V m.. [cell] membrane potential xii

14 LIST OF DRUGS USED ~ AF-DX 116 atropine Deb Cch forskolin Hexa histamine ICI 89,406 ICI 118,551 IDM Iso L-670,596 McN A343 nitrendipine norepinephrine oxotremorime phentolamine pirenzepine potassium chloride propranolol salbutamol timolol U46619 antagonist antagonist agonist agonist agonist antagonist ciyonist antagonist antagonist antagonist agonist antagonist agonist antagonist agonist agonist antagonist antagonist agonist antagonist agonist antagonist agonist site of action muscarinic receptors muscarinic receptors muscarinic receptors muscarinic receptors adenylate cyclase muscarinic receptors histamine receptors 8-adrenoceptors 8-adrenoceptors cyclo-oxygenase 8-adrenoceptors thromboxane receptors muscarinic receptors calcium channels adrenoceptors muscarinic receptors adrenoceptors muscarinic receptors membrane 8-adrenoceptors 8-adrenoceptors 8-adrenoceptors thromboxane receptors selectivity ~)M3)M, M,=~=M3 ~=M3) >M, M,=~=M3 8,=B 2 M, >)M 2 =M 3 voltage-operated c=b,=b 2 ~=M3»M, C) >8 M,) >M 2 =M 3 depolarizes 8,=8, 6 2 ) >6, 6,=6 2 xiii

15 INTRODUCTION (1) ASM Morphology The overall design of the respiratory system of vertebrates can be compared to that of an inverted tree, with large passages progressively dividing into ever more numerous and smaller passages. The largest of these is the trachea, which divides into the left and right bronchi. The latter, in turn, divide into a number of second order bronchi, each of which conduct air to one of the lobes of lung (six in total in the case of the canine species). The second order bronchi within each lobe then branch into third order, fourth order, etc., until the tissue becomes a tangled web of microscopic airways with sac-like terminations, referred to as alveoli, where gas exchange with the blood occurs. The innervation to the airways has a similar branching structure, which mirrors that of the airways. Finally, the arterial and venous systems invade the lungs at the same point where the second order bronchi enter each lobe, and then continue to follow the branching network of airway passages. In the airways used in this project, the pulmonary artery and the pulmonary vein were typically found immediately juxtaposed to the airway (and on opposite sides), which greatly facilitated dissection and excision of the tissue. It is important to keep in mind this overall structure, since there are regional differences with respect to structure and

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

Learning Outcomes. Systems Pharmacology PHAR3320. Nerves of the Respiratory Tract. Dr Fernandes

Learning Outcomes. Systems Pharmacology PHAR3320. Nerves of the Respiratory Tract. Dr Fernandes Systems Pharmacology PHAR3320 Nerves of the Respiratory Tract Dr Fernandes Learning Outcomes By the end of this lecture, students should be able to describe nerve pathways that innervate the airways discuss